Whole-brain radiotherapy for brain metastases: Evolution or revolution?

Paul D. Brown*, Manmeet S. Ahluwalia, Osaama H. Khan, Anthony L. Asher, Jeffrey S. Wefel, Vinai Gondi

*Corresponding author for this work

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

An estimated 20% of patients with cancer will develop brain metastases. Approximately 200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) each year to treat brain metastases. Historically, the prognosis of patients with brainmetastases has been poor; however, with new therapies, this is changing. Because patients are living longer following the diagnosis and treatment of brain metastases, there has been rising concern about treatment-related toxicities associated with WBRT, including neurocognitive toxicity. In addition, recent clinical trials have raised questions about the use ofWBRT. To better understand this rapidly changing landscape, this review outlines the treatment roles and toxicities of WBRT and alternative therapies for the management of brain metastases.

Original languageEnglish (US)
Pages (from-to)483-491
Number of pages9
JournalJournal of Clinical Oncology
Volume36
Issue number5
DOIs
StatePublished - Feb 10 2018

Fingerprint

Radiotherapy
Neoplasm Metastasis
Brain
Therapeutics
Complementary Therapies
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Brown, Paul D. ; Ahluwalia, Manmeet S. ; Khan, Osaama H. ; Asher, Anthony L. ; Wefel, Jeffrey S. ; Gondi, Vinai. / Whole-brain radiotherapy for brain metastases : Evolution or revolution?. In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 5. pp. 483-491.
@article{1aee4778d6f64649a808178752e20a7f,
title = "Whole-brain radiotherapy for brain metastases: Evolution or revolution?",
abstract = "An estimated 20{\%} of patients with cancer will develop brain metastases. Approximately 200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) each year to treat brain metastases. Historically, the prognosis of patients with brainmetastases has been poor; however, with new therapies, this is changing. Because patients are living longer following the diagnosis and treatment of brain metastases, there has been rising concern about treatment-related toxicities associated with WBRT, including neurocognitive toxicity. In addition, recent clinical trials have raised questions about the use ofWBRT. To better understand this rapidly changing landscape, this review outlines the treatment roles and toxicities of WBRT and alternative therapies for the management of brain metastases.",
author = "Brown, {Paul D.} and Ahluwalia, {Manmeet S.} and Khan, {Osaama H.} and Asher, {Anthony L.} and Wefel, {Jeffrey S.} and Vinai Gondi",
year = "2018",
month = "2",
day = "10",
doi = "10.1200/JCO.2017.75.9589",
language = "English (US)",
volume = "36",
pages = "483--491",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

Whole-brain radiotherapy for brain metastases : Evolution or revolution? / Brown, Paul D.; Ahluwalia, Manmeet S.; Khan, Osaama H.; Asher, Anthony L.; Wefel, Jeffrey S.; Gondi, Vinai.

In: Journal of Clinical Oncology, Vol. 36, No. 5, 10.02.2018, p. 483-491.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Whole-brain radiotherapy for brain metastases

T2 - Evolution or revolution?

AU - Brown, Paul D.

AU - Ahluwalia, Manmeet S.

AU - Khan, Osaama H.

AU - Asher, Anthony L.

AU - Wefel, Jeffrey S.

AU - Gondi, Vinai

PY - 2018/2/10

Y1 - 2018/2/10

N2 - An estimated 20% of patients with cancer will develop brain metastases. Approximately 200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) each year to treat brain metastases. Historically, the prognosis of patients with brainmetastases has been poor; however, with new therapies, this is changing. Because patients are living longer following the diagnosis and treatment of brain metastases, there has been rising concern about treatment-related toxicities associated with WBRT, including neurocognitive toxicity. In addition, recent clinical trials have raised questions about the use ofWBRT. To better understand this rapidly changing landscape, this review outlines the treatment roles and toxicities of WBRT and alternative therapies for the management of brain metastases.

AB - An estimated 20% of patients with cancer will develop brain metastases. Approximately 200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) each year to treat brain metastases. Historically, the prognosis of patients with brainmetastases has been poor; however, with new therapies, this is changing. Because patients are living longer following the diagnosis and treatment of brain metastases, there has been rising concern about treatment-related toxicities associated with WBRT, including neurocognitive toxicity. In addition, recent clinical trials have raised questions about the use ofWBRT. To better understand this rapidly changing landscape, this review outlines the treatment roles and toxicities of WBRT and alternative therapies for the management of brain metastases.

UR - http://www.scopus.com/inward/record.url?scp=85041901663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041901663&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.75.9589

DO - 10.1200/JCO.2017.75.9589

M3 - Review article

C2 - 29272161

AN - SCOPUS:85041901663

VL - 36

SP - 483

EP - 491

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -